IOBT
IO Biotech Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
Actual EPS |
---|
Consensus EPS |
Estimated EPS |
Number of Estimates |
EPS Surprise |
Stats
Summary
io biotech is a clinical stage biotech company developing disruptive immune therapies for immunological treatment of cancer. our pipeline of first-in-class immune modulating anti-cancer therapies is based on a unique platform technology enabling the activation of t cells that are specific for immune inhibitory molecules. io biotech has achieved a proven track record of progressing compounds to the clinic, and has two lead immune modulating anti-cancer therapies targeting ido and pd-l1 in clinical development and several compounds finalizing preclinical phase. io biotech has an experienced management team within immuno-oncology fields and a world-class advisory board.
Market Cap: 109 Million
Primary Exchange: NASDAQ
Website: iobiotech.com
Shares Outstanding: 65.9 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 0.9151375436940957
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Ethical Flags
Longest drawdown: 732 trading days
From: 2021-11-08 To: 2024-03-07
Lowest Point:
Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
---|
Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
---|